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Running title: Cost-effectiveness of adjuvant capecitabine in CRC 
 Oral capecitabine (Xeloda®) is an effective drug with favourable safety in adjuvant 
and metastatic colorectal cancer. Oxaliplatin-based therapy is becoming standard for 
Dukes’ C colon cancer in patients suitable for combination therapy, but is not yet 
approved by the UK National Institute for Health and Clinical Excellence (NICE) in 
the adjuvant setting. Adjuvant capecitabine is at least as effective as 5-
fluorouracil/leucovorin (5-FU/LV), with significant superiority in relapse-free survival 
and a trend towards improved disease-free and overall survival. We assessed the 
cost-effectiveness of adjuvant capecitabine from payer (UK National Health Service 
[NHS]) and societal perspectives. We used clinical trial data and published sources 
to estimate incremental direct and societal costs and gains in quality-adjusted life 
months (QALMs). Acquisition costs were higher for capecitabine than 5-FU/LV, but 
higher 5-FU/LV administration costs resulted in 57% lower chemotherapy costs for 
capecitabine. Capecitabine vs 5-FU/LV-associated adverse events required fewer 
medications and hospitalisations (cost savings £3653). Societal costs, including 
patient travel/time costs, were reduced by >75% with capecitabine vs 5-FU/LV (cost 
savings £1318), with lifetime gain in QALMs of 9 months. Medical resource utilisation 
is significantly decreased with capecitabine vs 5-FU/LV, with cost savings to the NHS 
and society. Capecitabine is also projected to increase life expectancy vs 5-FU/LV. 
Cost savings and better outcomes make capecitabine a preferred adjuvant therapy 
for Dukes’ C colon cancer. This pharmacoeconomic analysis strongly supports 
replacing 5-FU/LV with capecitabine in the adjuvant treatment of colon cancer in the 
UK. 
 
Keywords: capecitabine; 5-fluorouracil/leucovorin; adjuvant; colon cancer; 
pharmacoeconomics; cost-effectiveness 
The current global standard adjuvant treatment for Dukes’ C (stage III) colon cancer 
is intravenous (i.v.) administration of bolus 5-fluorouracil (5-FU) and leucovorin (LV), 
either weekly or monthly, over a period of 6–8 months (Van Cutsem et al, 2002). 
Adjuvant 5-FU/LV reduces the risk of relapse and prolongs survival in patients with 
resected colon cancer (IMPACT, 1995; O’Connell et al, 1997; Haller et al, 1998; 
Wolmark et al, 1999; Porschen et al, 2001; Arkenau et al, 2003). 
Although the clinical benefits associated with adjuvant 5-FU/LV are significant, it 
is clear that more effective, convenient and better-tolerated treatments are required. 
Capecitabine (Xeloda®, F. Hoffmann-La Roche, Basel, Switzerland) is a convenient 
oral fluoropyrimidine that generates 5-FU preferentially in tumour tissue through a 
three-step enzymatic cascade (Miwa et al, 1998). As first-line therapy for metastatic 
colorectal cancer, oral capecitabine achieved improved response rates (26 vs 17%, 
respectively), and equivalent progression-free and overall survival compared with 
monthly bolus i.v. 5-FU/LV (Van Cutsem et al, 2004). Capecitabine was also better 
tolerated than 5-FU/LV and its administration was associated with a reduced 
consumption of medical resources (Twelves et al, 2001). These results led to the 
approval of capecitabine in 2001 as a first-line alternative to 5-FU/LV in metastatic 
colorectal cancer. 
The effectiveness of capecitabine in the metastatic setting provided a rationale for 
its use as adjuvant therapy for colon cancer. A large, randomised phase III study (X-
ACT) was undertaken to compare the efficacy and tolerability of adjuvant oral 
capecitabine vs bolus i.v. 5-FU/LV (Mayo Clinic regimen) over 24 weeks in 1987 
patients with Dukes’ C colon cancer (Twelves et al, 2005). This study demonstrated 
that capecitabine is at least as effective as 5-FU/LV with significant superiority in 
relapse-free survival (P = 0.0407) and a trend towards improved disease-free (P = 
0.0528) and overall survival (P = 0.0706). In addition, an improved safety profile was 
noted in favour of capecitabine (Twelves et al, 2005; Scheithauer et al, 2003). 
On 31 March 2005, capecitabine received approval for the adjuvant treatment of 
Dukes’ C colon cancer from the European Medicines Agency (EMEA) Committee for 
Medicinal Products for Human Use (CHMP). Capecitabine was also recently 
approved as a single agent for the adjuvant treatment of Dukes’ C colon cancer by 
the US Food and Drug Administration (FDA) in patients ‘who have undergone 
complete resection of the primary tumour, when treatment with fluoropyrimidine 
therapy alone is preferred’. Patients have long expressed a preference for oral 
fluoropyrimidine therapy instead of i.v. treatment (Liu et al, 1997; Borner et al, 2002) 
and oncologists in Europe and the US are now in a better position to satisfy this 
preference. 
Clearly, the results of the X-ACT trial suggest that capecitabine can be used 
instead of 5-FU/LV in the adjuvant treatment of Dukes’ C colon cancer, and we have 
seen that oral treatment is preferable from the point of view of most patients. 
However, with ever-increasing pressures to control medical costs, the decision of 
whether or not to use a treatment may not be based on clinical effectiveness alone. 
Medical guidelines and treatment decision-making increasingly give consideration to 
economic costs associated with achieving the health benefits of a therapy. The 
National Institute for Health and Clinical Excellence (NICE), for example, considers 
‘how well the medicine or treatment works in relation to how much it costs the 
National Health Service (NHS)’ (NICE, 2005). These comparisons of cost-
effectiveness can reveal the balance between costs and savings among alternative 
treatments and thereby assist healthcare providers in prioritising use of available 
medical resources to maximise health gain (Siegel et al, 1996; Weinstein et al, 1996). 
Using data collected prospectively during the X-ACT trial, we undertook this 
pharmacoeconomic analysis to evaluate the cost-effectiveness of adjuvant 
capecitabine vs standard adjuvant therapy (bolus 5-FU/LV [Mayo Clinic regimen]) in 
patients with Dukes’ C colon cancer, from the UK NHS perspective, as well as from a 
societal perspective.  
 
PATIENTS AND METHODS 
Medical resource use and cost-effectiveness analyses were conducted as part of a 
prospective pharmacoeconomic evaluation of the X-ACT study. In brief, the X-ACT 
study was an open-label, multinational, randomised, phase III trial of adjuvant 
therapy for resected, histologically confirmed Dukes’ C colon carcinoma (Twelves et 
al, 2005; Scheithauer et al, 2003). Patients were randomised to 24 weeks’ treatment 
with either 8 cycles of oral capecitabine 1250 mg m-2 twice daily, days 1–14 every 21 
days (n = 1004), or 6 cycles of rapid-infusion i.v. LV 20 mg m-2 followed immediately 
by i.v. bolus 5-FU 425 mg m-2, days 1–5 every 28 days (Mayo Clinic regimen) (n = 
983). 
 
Design and structure of the pharmacoeconomic model  
A health-state transition model was developed to assess healthcare costs, quality-
adjusted survival and overall cost-effectiveness of capecitabine compared with 5-
FU/LV. The model consists of three health states – stable (pre-relapse; disease and 
relapse free), post-relapse and death, with further subclassification of the post-
relapse category into relapse (i.e. during subsequent treatment for metastatic colon 
cancer), remission and the 12-month period before death. A relapse event was 
classified as instances of relapse, new colon cancer or death due to colon cancer or 
treatment. These health states allowed us, in effect, to partition overall survival into 
pre- and post-relapse periods, using the relapse-free and overall survival data for 
capecitabine and 5-FU/LV observed in the X-ACT clinical trial. The model 
incorporates costs during chemotherapy using the medical resource utilisation data 
collected during the X-ACT clinical trial. In addition, possible outcomes for post-
chemotherapy costs were considered for the post-relapse health states. 
The time spent in each health state was estimated by extrapolating the relapse-
free and overall survival follow-up data from the X-ACT clinical trial to a lifetime 
horizon. Health outcomes were measured as life months (LMs) gained and quality-
adjusted life months (QALMs) gained, where QALMs are a measure of the time spent 
in each health state, weighted by the quality of life (utility) in that health state. The 
incremental cost-effectiveness ratio, measured as the cost per QALM gained, was 
estimated by dividing the difference in total costs in each arm by the increase in 
survival for treatment with capecitabine compared with 5-FU/LV. Technically, a 
meaningful incremental cost-effectiveness ratio cannot be calculated if a therapy 
being evaluated is found to be cost-saving or cost-neutral (i.e. negative or zero 
numerator) and either more or equally effective (i.e. positive or zero denominator). 
When a therapy is cost-saving and more effective, it is termed ‘dominant’ because it 
is clearly preferred. 
 
Medical resource use and costs 
The unit costs for medical resource utilisation during treatment are detailed in Table 
1. Safety and medical resource use data were collected prospectively during the X-
ACT clinical trial, throughout treatment and for 28 days after the last intake of study 
drug. Data were recorded at all study centres on case report forms. Data were 
collected on study drug administration (including cumulative dose, infusion duration 
and frequency), hospital admissions (including length of stay) and visits to providers 
and outpatient consultations for treatment-related adverse events (AEs). 
Consultations were categorised according to the type of healthcare provider (e.g. 
general practitioner, specialist or allied health professional) and location (e.g. 
emergency unit, home visit or clinic visit). It was assumed, based on expert opinion, 
that 5% of patient visits to hospital would have required ambulance transportation. 
Chemotherapy drug costs were taken from the Monthly Index of Medical 
Specialties (September 2004), with costs for consultations, hospitalisations, accident 
and emergency care and ambulance transportation derived from Unit Costs of Health 
and Social Care published by the UK-based Personal Social Services Research Unit 
(Netten and Curtis, 2004). Cost of i.v. administration was taken from the UK 
Department of Health National Tariff (DOH, 2005). In the UK, patients receiving 
capecitabine see a specialist for a consultation and patients treated with 5-FU/LV go 
to an outpatient clinic in a hospital for i.v. administration. In addition, patients 
receiving 5-FU/LV will see a specialist during some of their drug administration visits. 
In the base case, it was assumed that 5-FU/LV patients would see a specialist for the 
same number of visits as patients receiving capecitabine, in addition to going to the 
outpatient clinic for i.v. administration. 
The model also considered drugs used in the management of treatment-related 
AEs; the selection of drugs to be included in the model was based on expert 
clinical/pharmacist judgement. Within a class of drugs, the drug most commonly used 
in the clinical trial was used to estimate the unit cost in that class. The total cost of 
each medication was calculated by multiplying the daily cost of treatment by the total 
number of days of treatment used in each arm. This was then divided by the number 
of patients in the relevant treatment arm to provide the mean cost per patient. 
Assumptions for the post-treatment costs were based on previously published 
lifetime costs of colorectal cancer (Etzioni et al, 2001; Ramsey et al, 2002). Costs 
associated with relapse were based on assumptions derived from a study reporting 
the cost-effectiveness of oxaliplatin/5-FU/LV in the adjuvant treatment of colorectal 
cancer (Aballea et al, 2005). For the base case, the assumptions were: £100 monthly 
maintenance cost during pre-relapse, £25 000 average cost during the relapse 
period, £200 monthly maintenance cost during post-relapse; and £10 000 average 
cost during the last 12 months of life. 
 
Societal costs 
From a societal perspective, the model also considered indirect costs borne by the 
patient, such as cost of travel and time for outpatient and drug administration visits. 
Time assumptions included travel time, as well as waiting and encounter time and 
was assumed to be 1.5 hours for outpatient visits for management of AEs, 8 hours 
for hospitalisations for management of AEs and 2 and 4 hours, respectively, for 
capecitabine consultation and 5-FU/LV administration visits (Twelves et al, 2003). 
The value assigned to this time was £12 per hour based on average hourly 
compensation in the UK. This information, together with the number of outpatient, 
hospital and drug administration visits in each treatment arm was used to determine 
the mean number of hours per patient in each treatment arm and the cost of this 
time. For travel costs, a 30-mile round trip was assumed and was assigned a value of 
£0.23 per mile. This information, together with the number of outpatient, hospital and 
drug administration visits in each treatment arm was used to determine the total 
travel cost per patient in each treatment arm. 
 
Survival analysis 
The time a patient spent in each health state was estimated using partitioned survival 
analysis of the trial data (intent-to-treat population), with projections beyond the trial 
period for 5-year, 10-year and lifetime horizons. In effect, this analysis estimates the 
area under the time-to-event curves at each horizon for relapse and overall survival, 
and then derives the post-relapse time by subtracting the former from the latter. 
These extrapolations were based on fitting a log-normal distribution to the relapse-
free and overall survival data for the capecitabine and 5-FU/LV treatment groups. 
These data were used to determine the amount of time that the average patient 
would spend in the pre- and post-relapse health states. 
 
Quality of life (utility) 
Utility values for the health states were derived from the published literature (Ramsey 
et al, 2000). For both arms, it was assumed that utility was 0.8 during chemotherapy 
and was 0.86 during the stable (pre-relapse) health state. An overall average utility of 
0.59 was assumed for the post-relapse health states. 
 
Discounting 
Discounting for the time value of money was applied to both cost and outcomes, 
according to the guidelines issued by the NICE, in order to compare alternative future 
levels of costs and benefits. In this analysis, an annual discount rate of 1.5% was 
applied to benefits and an annual discount rate of 6.0% was applied to all costs.  
 
Sensitivity analyses 
One-way and multi-way sensitivity analyses were performed to test the robustness of 
the model. The sensitivity analyses widely varied key assumptions in the model, 
including time horizon, key cost parameters (during treatment and post-treatment) 
and overall cost-effectiveness. 
 
RESULTS 
From November 1998 to November 2001, a total of 1987 patients were enrolled into 
the X-ACT study at 164 centres worldwide. The capecitabine and 5-FU/LV treatment 
arms included 1004 and 983 patients, respectively, and the treatment arms were well 
balanced. The efficacy and safety results have been reported previously (Twelves et 
al, 2005; Scheithauer et al, 2003).  
 
Chemotherapy costs 
Although the mean cost of chemotherapy drugs per patient was higher in the 
capecitabine arm (£2081 compared with £602 in the 5-FU/LV arm), the mean number 
of treatment administration visits was increased almost four-fold with the i.v. 5-FU/LV 
regimen (28 visits in 6 months) compared with capecitabine (7.4 visits in 6 months) 
(Figure 1). This resulted in increased costs for chemotherapy administration in the 5-
FU/LV arm compared with the capecitabine treatment arm (£5151 and £419, 
respectively). Thus, considering both drugs and their administration, chemotherapy 
costs are lower by £3253 (57% lower) for capecitabine vs 5-FU/LV. 
 
Cost of managing adverse events 
The improved safety profile with capecitabine compared with 5-FU/LV was reflected 
in the need for fewer costly medications for the management of treatment-related 
AEs in the capecitabine treatment arm compared with 5-FU/LV (Table 2). In 
particular, capecitabine reduced the need for the more expensive drugs, such as 
fluconazole for stomatitis, 5-HT3 antagonists for nausea/vomiting and cytokines for 
neutropenia. Overall, the mean cost of medication for management of AEs was lower 
in the capecitabine arm compared with the 5-FU/LV arm (£86 and £345, 
respectively). 
A similar mean number of physician visits due to AEs were seen in each 
treatment arm (1.93 and 1.92 for capecitabine and i.v. 5-FU/LV, respectively). 
However, there were 16% fewer AE-related hospital admissions and 15% fewer days 
in hospital in the capecitabine treatment arm vs the i.v. 5-FU/LV arm (10.6 and 12.8 
admissions, respectively, and 113 vs 130 days, respectively; Figure 2). The mean 
cost of hospitalisations was consequently lower with capecitabine than with 5-FU/LV 
(£399 vs £459), although the cost of physician consultations was slightly increased 
with capecitabine compared with 5-FU/LV (£154 vs £145). In accordance with these 
findings, the projected ambulance costs would be reduced in the capecitabine group 
compared with the 5-FU/LV group (£38 vs £126). 
 
Societal costs for time and travel 
The projected mean number of hours per patient required for travel were lower in the 
capecitabine group compared with the 5-FU/LV group (27 and 125 hours, 
respectively) and the mean costs for travel time were therefore reduced in the 
capecitabine group (£320 compared with £1503 in the 5-FU/LV group). Similarly, the 
mean travel cost per patient was reduced with capecitabine compared with 5-FU/LV 
(£62 and £196, respectively).  
 
Total costs 
Direct costs during the treatment period have been grouped into six components, as 
illustrated in Table 3. The major drivers for the cost analysis are the cost of the 
chemotherapy drugs and the cost of administration of treatment. The additional  
£4732 required for i.v. therapy is more than three times the additional acquisition cost 
of capecitabine. With respect to the management of AEs, the most notable difference 
was the lower cost of medication used for treating AEs in the capecitabine arm (£86 
compared with £345 in the 5-FU/LV arm). Overall, from an NHS perspective during 
the treatment period alone, oral treatment with capecitabine is projected to be cost-
saving by an average amount of approximately £3653 per patient. From a societal 
perspective, capecitabine treatment was associated with cost savings of £1184 and 
£134 for time and travel costs, respectively, yielding cost savings per patient of 
approximately £4971. 
Considering post-treatment costs as well as costs during treatment, the projected 
direct cost saving for the NHS from a lifetime perspective is projected to be £3608 
per patient. From a societal perspective, the lifetime cost savings are even greater: 
£4925 per patient. 
 
Clinical effectiveness 
In terms of overall survival, the Kaplan-Meier projection was 81.3% of patients 
receiving capecitabine surviving at 36 months compared with 77.6% of patients 
receiving i.v. 5-FU/LV, an absolute difference of 3.7%. In the fitted model, the 
projected survival gains with capecitabine by 36 and 48 months were 0.5 QALMs and 
0.8 QALMs, respectively (Figure 3). When the fitted model is used to extrapolate to 
longer horizons, e.g. 5 years, 10 years or lifetime, the projected gain in QALMs 
continues to increase with capecitabine, even after taking into account adjustments 
for quality of life and discounting. Over a lifetime, for example, the QALM advantage 
for capecitabine widens to 9 months. 
 
Sensitivity analyses 
Table 4 shows the impact of varying model estimates on short-term costs and 
QALMs. Varying drug acquisition costs for study drugs and medications for 
management of AEs had only a marginal effect on short-term cost savings: the total 
cost savings were £14 637 and £14 590 at the 5th and 95th percentiles, respectively. 
A 20% variation in cost per drug administration visit, however, yielded an almost two 
fold variation (£4577–£2707). Overall, the sensitivity analyses confirmed substantial 
cost savings for oral capecitabine vs 5-FU/LV. These analyses also confirmed that 
the substantial QALM advantage for capecitabine vs 5-FU/LV would be maintained 
even in the face of variation of health state utilities and the discount rate for costs and 
benefits. 
The results of the multi-way sensitivity analysis for post-treatment costs are 
shown in Table 5. These results demonstrate that the long-term cost advantages of 
capecitabine are lowest when the costs of relapse and maintenance are low. It is 
clear that even under rigorous multi-way sensitivity testing, capecitabine remains a 
robust, cost-saving treatment option compared with 5-FU/LV.  
 
DISCUSSION 
From a UK NHS perspective, this pharmacoeconomic analysis projects that the use 
of capecitabine for adjuvant treatment of colon cancer would not only save direct 
medical costs, but also improve health outcomes compared with 5-FU/LV. In 
economic terms, capecitabine would be termed a ‘dominant’ (cost-saving and more 
effective) treatment strategy, taking its place among other cost-effectiveness 
benchmarks in oncology (Table 6). The immediate savings on NHS costs during the 
treatment period with capecitabine would be approximately £3700 per patient. From 
a societal perspective that also considers patient time and travel costs, the savings 
would increase to nearly £5000 per patient. In addition, the projected 3.7% absolute 
improvement in the patient survival outcome observed during the trial period should 
yield an equivalent of over 9 months of additional survival over a lifetime, after 
discounting for the time value of money and adjusting for possible quality of life 
changes due to later relapse. 
The key drivers of the dominant cost-effectiveness results of capecitabine in 
comparison with 5-FU/LV are firstly the savings achieved by avoiding the cost of the 
i.v. Mayo Clinic regimen for 5-FU/LV, and secondly the projection of improved 
survival. These are both substantial benefits in comparison to the acquisition cost of 
capecitabine. The favourable safety profile of capecitabine also translates into lower 
costs for AEs due to fewer hospitalisations and lower associated medication costs. 
However, considering costs after the treatment period essentially has a cost neutral 
impact in the base case: the additional costs of living longer on capecitabine are 
about the same as the additional costs of earlier and more frequent relapses and 
death on 5-FU/LV. 
In the short term, the critical comparison is between the higher drug acquisition 
cost of capecitabine (£2081 compared with £602 for 5-FU/LV) and the additional 
costs for the 28 5-FU/LV infusions (£4732) received by the average patient in the 5-
FU/LV treatment arm of the X-ACT trial. We assume that these are provided in an 
outpatient setting in the UK and that the cost to the NHS is £169 per administration. 
However, even if the infusion administration costs were as little as one half of this 
value, the cost would still be greater than the acquisition cost of capecitabine. 
The way in which funding is provided in NHS hospitals, e.g. reimbursement for 
day case attendances, provides some disincentive for them to take a broader NHS 
perspective, much less the even broader societal perspective. Nonetheless 
prescribing committees, hospitals and other policy makers should be encouraged to 
take a broader perspective. Tight prescribing budgets can mean that acquiring 
approval to switch to capecitabine is difficult but the additional benefits for patients 
should be weighed in any such decision. Furthermore, although staff costs may be 
fixed, freeing up their time will allow them to treat more cancer patients quickly and 
thereby help to reduce waiting lists to government targets. 
The other key driver in assessing cost-effectiveness is the projection of improved 
survival. Although there was only a strong statistical trend towards a survival 
advantage in the X-ACT trial at 3 years of follow-up, it is important to consider the 
corroborating evidence. First, the projected survival advantage is reflected in all 
three, presumably related, measures of disease-free, relapse-free and overall 
survival (Sargent et al, 2004). Second, the correlation among these is consistent with 
previous studies of adjuvant 5-FU/LV in colon cancer. Third, the outcome in the 
control arm is similar to previous studies using the Mayo Clinic regimen (Haller et al, 
1998). Furthermore, the strength of the statistical trend was reinforced by the finding 
that covariate-adjusted survival was significantly superior with capecitabine vs 5-
FU/LV (hazard ratio 0.788, P = 0.0208; Twelves et al, 2005). 
The estimation of the quantitative impact on survival required extrapolation 
beyond the observed trial period. In similar studies, investigators have approached 
this in a variety of ways; there is no uniform methodology. We used the approach of 
fitting a curve to the observed data and extrapolating to the end of life. Both the log-
normal and Weibull survival curves are commonly used for this, so both were 
tried. The fit during the trial period was slightly better for the log-normal curve so this 
was used in the base case. However, the log-normal distribution yielded a gain of 9 
QALMs, while the Weibull distribution produced 10.9 QALMs, suggesting that the 
overall survival results were not sensitive to this choice and were possibly 
conservative. 
The improved survival rates observed with capecitabine, together with the cost 
savings identified in this and other analyses, render it a viable alternative to 5-FU/LV 
both as a single agent and in combination. Preliminary phase III data have shown the 
combination of oxaliplatin and infusional 5-FU/LV (FOLFOX) to be effective in the 
adjuvant setting (Sastre et al, 2005; Arkenau et al, 2005; Ducreux et al, 2005). 
Replacing 5-FU/LV with capecitabine in this combination is promising not only 
clinically, but also economically, as additional infusion and time costs would be 
avoided. 
One limitation of this model is the lack of direct measures of utility in the stable 
(pre-relapse) health state following treatment. Based on the literature, we imputed a 
relatively high utility value of 0.86 for this health state, which was assumed for both 
arms. Thus, any impact would be due to the duration of time in this health state, vs 
the time in the post-relapse health state. The post-relapse value was also imputed 
from the literature to be 0.59, which is similar to the values reported for patients on 
chronic renal dialysis. Treatment phase utility was assumed to be the same in both 
arms: 0.80. 
The use of a societal perspective to measure the time and travel costs associated 
with the treatments illustrates the advantage of oral over infusion treatment. On 
average, patients receiving oral therapy are estimated to spend around 99 fewer 
hours either receiving treatment or in treatment-related travel. Valued at average 
market compensation, this amounts to an additional cost saving of about £1300, 
which is treated here as a cost to society. It could well be the case that many patients 
would also regard this impact as representing some degree of utility loss with infusion 
therapy, reflecting a negative impact on their quality of life during the treatment 
period. The calculations do not take account of such an effect: only the opportunity 
cost of the time spent is projected. 
This pharmacoeconomic analysis found that capecitabine is a dominant (cost 
saving and more effective) therapy compared with 5-FU/LV from both the NHS and 
societal perspectives. These results are further supported by other analyses in the 
Italian healthcare setting, where capecitabine was also found to be cost-saving by 
€2234 per adjuvant treatment (data on file) and in the US, where capecitabine was 
projected to be a cost-effective therapy from a payer and societal perspective 
(Garrison et al, 2005). Based on these data, the replacement of 5-FU/LV with 
capecitabine in the adjuvant treatment of colon cancer in the UK would be cost-
saving and produce better outcomes and hence be strongly cost-effective and 
preferred.
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Table 1 Unit cost estimates for medical resource utilisation  
       Capecitabine 
(£) 5FU/LV (£)  
Chemotherapy per g1  £4.93 £382.20 
Visits for drug administration  
 Physician consultation2  £57 £57 
 i.v. administration visit3  £0 £169 
Hospitalisation: cost per day2  £354 
Provider consultations 
 GP (office)2  £21 
   GP (home visit)2  £65 
   Specialist (office)2  £57 
 Day care2  £169 
 Accident and emergency2  £83 
   Nurse/other office consultation2  £9 
 Nurse/other home visit2  £20 
Ambulance (round trip)2  £86 
1Monthly Index of Medical Specialties, September 2004; 2Netten and Curtis, 2004; 3The Health Service 
Database, 2005 
Table 2 Medications used for management of treatment-related adverse events. 
 
Days of use per 100 patients 
Medication 
Capecitabine 
(n = 995) 
5-FU/LV 
(n = 974) 
Anti-
emetics/antidiarrhoeals 1933 2534 
Dermatologicals/emollients 951 229 
Benzodiazapines 152 245 
Stomatologicals/triazoles 140 775 
Antibiotics/cephalosporins 128 133 
Cytokines/growth factors 5 21 
Octreotide 8 8 
Total 3317 3945 
 
Table 3 Results of the cost-effectiveness analysis: costs during treatment 
  Cost impact of capecitabine treatment for 
colorectal cancer in  
adjuvant therapy (per patient), £ 
 
 Capecitabine 5-FU/LV Net cost savings 
Cost of 
chemotherapy 
drugs 
2081 602 -1479 
Cost of visits for 
study drug 
administration 
419 5151 4732 
Cost of hospital use 399 459 61 
Cost of physician 
consultations for 
adverse events 
154 145 -9 
Cost of medication 
for treating adverse 
events 
86 345 260 
D
ire
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 c
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 to
 th
e 
N
H
S 
Cost of ambulance 
trips 38 126 88 
Cost of time 319 1503 1184 
So
ci
et
al
 
co
st
s 
Cost of travel 62 196 134 
 Total costs* 3557 8528 4971 
* Numbers may differ because of rounding 
 Sub-total* 3176 6829 3653 
Table 4 Results of one-way sensitivity analyses 
Parameter Range Short-term cost savings 
Lifetime 
QALMs 
Mean mg of 
capecitabine use 430 137–414 180 
£3614–£3693 No change–No 
change 
Mean mg of 5-FU use 19 820–19 147 £3658–£3649 No change–No change 
Mean mg of LV use 973–937 £3660–£3647 No change–No change 
Heath state utilities +20%–20% No change–No change 10.9–6.7 
Cost per drug 
administration visit +20%–20% 
£4577–£2707 No change–No 
change 
Discount rate for costs 
and benefits 3.5% 
£3899 (long-term 
cost savings) 6.5 
Total AE medication 
cost +20%–20% 
£3705–£3601 No change–No 
change 
QALMs Weibull 
distribution 
No change 10.9 
 
Table 5 Results of multi-way sensitivity analysis for post-treatment costs 
Post-treatment cost parameters (£) Lifetime cost 
savings (£) 
Pre-relapse 
monthly 
savings 
Relapse 
period 
Post-relapse 
monthly 
maintenance 
Last year of 
life  
100 (base 
case) 25 000 
200 10 000 3608 
100 10 000 200 5000 2973 
200 10 000 400 5000 1813 
100 40 000 200 15 000 4242 
50 25 000 100 10 000 4185 
50 40 000 100 15 000 4819 
 
Table 6 Cost-effectiveness benchmarks in oncology  
 Cancer setting Life-expectancy gain (months) 
Cost per life 
year gained 
Capecitabine vs 5-FU/LV Colon adjuvant 8.7* Dominant† 
FOLFIRI vs 5-FU/LV1 Colorectal metastatic 2.6 £29 000
 
AT vs AC1 Breast metastatic N/A £19 000
 
CMF vs observation2 Breast adjuvant 3.6 US$447 
Chemotherapy vs 
observation3 Breast adjuvant 5.1* US$15 400* 
 
N/A = not available 
* Quality-adjusted values 
† Cost saving and more effective in terms of quality-adjusted life months 
1National Institute for Health and Clinical Excellence; 2Messori et al 1996; 3Hillner et al 1991 
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Figures 
Figure 1 Number of treatment visits for chemotherapy administration or adverse 
events with capecitabine versus 5-FU/LV 
 Figure 2 Hospital admissions for adverse events 
 Figure 3 Net gain with capecitabine compared with 5-FU/LV in quality-adjusted life 
months by model horizon 
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